Log In
Print this Print this

InRhythm, inhaled flecainide

  Manage Alerts
Collapse Summary General Information
Company InCarda Therapeutics Inc.
DescriptionInhaled formulation of antiarrhythmic drug flecainide
Molecular Target Nav1.5 (SCN5A) ; Ryanodine receptor 2 (RyR2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationFibrillation
Indication DetailsTreat recent onset paroxysmal atrial fibrillation
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today